p53 and ovarian carcinoma survival : an Ovarian Tumor Tissue Analysis consortium study
Köbel, Martin (Foothills Medical Center (Calgary, Canadà))
Kang, Eun-Yyoung (University of Calgary (Calgary, Canadà))
Weir, Ashley (The Walter and Eliza Hall Institute of Medical Research (Victoria, Austràlia))
Rambau, Peter F. (Catholic University of Health and Allied Sciences-Bugando (Mwanza, Tanzània))
Lee, Cheng-Han (University of Alberta)
Nelson, Gregg S. (University of Calgary (Calgary, Canadà))
Ghatage, Prafull (University of Calgary)
Meagher, Nicola S. (The University of Sydney (Sydney, Austràlia))
Riggan, Mrjorie J. (Duke University Medical Center (Durham, Estats Units d'Amèrica))
Alsop, Jennifer (University of Cambridge (cambridge, Regne Unit))
Anglesio, Michael (University of British Columbia (Vancover, Canadà))
Beckmann, Matthias W. (University Hospital Erlangen (Erlangen, Alemanya))
Bisinotto, Christiani (University of São Paulo (Ribeirão Preto, Brasil))
Boisen, Michelle (University of Pittsburgh School of Medicine (Pittsburgh, Estats Units d'Amèrica))
Boros, Jessica (The University of Sydney (Sydney, Austràlia))
Brand, Alison H. (The University of Sydney (Sydney, Austràlia))
Brooks-Wilson, Angela (Canada's Michael Smith Genome Sciences Centre. BC Cancer (Vancover, Canadà))
Carney, Michael E. (University of Hawaii (Honolulu, Estats Units d'Amèrica))
Coulson, Penny (The Institute of Cancer Research (londres, anglaterra))
Courtney-Brooks, Madeleine (University of Pittsburgh School of Medicine (Pittsburgh, Estats Units d'Amèrica))
Cushing-Haugen, Kara L. (Fred Hutchinson Cancer Research Center)
Cybulski, Cezary (Pomeranian Medical University (Szczecin, Polònia))
Deen, S. (Queen's Medical Centre)
El-Bahrawy, M.A. (Hammersmith Hospital (Londres))
Elishaev, E. (University of Pittsburgh School of Medicine)
Erber, R. (University Hospital Erlangen (Alemanya))
Fereday, Sian (The University of Melbourne)
Fischer, A. (Tuebingen University Hospital)
Gayther, S.A. (Cedars-Sinai Medical Center)
Barquin-Garcia, A. (University Hospital)
Gentry-Maharaj, A. (University College London)
Gilks, C.B. (University of British Columbia)
Gronwald, H. (Pomeranian Medical University)
Grube, M. (Tuebingen University Hospital)
Harnett, P.R. (Westmead Hospital)
Harris, H.R. (University of Washington)
Hartkopf, A.D. (University Hospital of Ulm (Alemanya))
Hartmann, Andreas (University Hospital Erlangen (Alemanya))
Hein, A. (University Hospital Erlangen (Alemanya))
Hendley, J. (Peter MacCallum Cancer Centre)
Hernandez, B.Y. (University of Hawaii Cancer Center)
Huang, Y. (Mayo Clinic (Rochester, Estats Units d'Amèrica))
Jakubowska, A. (Pomeranian Medical University)
Jimenez-Linan, M. (Addenbrookes Hospital (Cambridge, Regne Unit))
Jones, M.E. (The Institute of Cancer Research)
Kennedy, C.J. (The University of Sydney)
Kluz, T. (Medical College of Rzeszow University)
Koziak, J.M. (Alberta Health Services-Cancer Care)
Lesnock, J. (University of Pittsburgh School of Medicine)
Lester, J. (University of California at Los Angeles)
Lubiński, J. (Pomeranian Medical University)
Longacre, T.A. (Stanford University School of Medicine)
Lycke, M. (University of Gothenburg)
Mateoiu, C. (University of Gothenburg)
McCauley, B.M. (Mayo Clinic (Rochester, Estats Units d'Amèrica))
McGuire, V. (Stanford University School of Medicine)
Ney, B. (Tuebingen University Hospital)
Olawaiye, A. (University of Pittsburgh School of Medicine)
Orsulic, S. (University of California at Los Angeles)
Osorio, A. (Instituto de Salud Carlos III)
Paz-Ares, L. (Hospital 12 de Octubre (Madrid))
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau)
Rothstein, J.H. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
Ruebner, M. (University Hospital Erlangen (Alemanya))
Schoemaker, M.J. (The Institute of Cancer Research)
Shah, M. (University of Cambridge)
Sharma, R. (Westmead Hospital)
Sherman, M.E. (Mayo Clinic Florida (Jacksonville, Estats Units d'Amèrica))
Shvetsov, Y.B. (University of Hawaii Cancer Center)
Singh, N. (University of British Columbia)
Steed, H. (Alberta Health Services)
Storr, S.J. (University of Nottingham)
Talhouk, Aline (University of British Columbia (Vancover, Canadà))
Traficante, Nadia (The University of Melbourne (Melbourne, Austràlia))
Wang, Chen (Mayo Clinic (Rochester, Estats Units d'Amèrica))
Whittemore, Alice S. (Stanford University School of Medicine (Stanford, Estats Units d'Amèrica))
Widschwendter, Martin (University of Innsbruck (Innsbruck,Àustria))
Wilkens, Lynne R. (University of Hawaii Cancer Center (Honolulu, Estats Units d'Amèrica))
Winham, Stacey J. (Mayo Clinic (Rochester, Estats Units d'Amèrica))
Benitez, Javier (Centro Nacional de Investigaciones Oncológicas)
Berchuck, Andrew (Duke University Medical Center (Durham, Estats Units d'Amèrica))
Bowtell, David D. (The University of Melbourne (Melbourne, Austràlia))
Candido dos Reis, Francisco J. (University of São Paulo (Ribeirão Preto, Brasil))
Campbell, Ian (The University of Melbourne (Melbourne, Austràlia))
Cook, Linda S. (University of Calgary (Calgary, Canadà))
deFazio, Anna (The University of Sydney (Sydney, Austràlia))
Doherty, Jennifer A. (University of Utah (Salt Lake City, Estats Units d'Amèrica))
Fasching, Peter A. (University Hospital Erlangen (Erlangen, Alemanya))
Fortner, Renée T. (Cancer Registry of Norway (Oslo, Noruega))
García, María J. (Spanish National Cancer Research Centre (Madrid))
Goodman, Marc T. (Cedars-Sinai Medical Center (Los Angeles, Estats Units d'Amèrica))
Goode, Ellen L. (Mayo Clinic (Rochester, Estats Units d'Amèrica))
Gronwald, Jacek (Pomeranian Medical University (Szczecin, Polònia))
Huntsman, David G. (BC Cancer Research Centre (Vancover, Canadà))
Karlan, Beth Y. (University of California at Los Angeles (Los Angeles, Estats Units d'Amèrica))
Kelemen, Linda E. (South Carolina Department of Health & Environmental Control (Columbia, Estats Units d'Amèrica))
Kommoss, Stefan (Tuebingen University Hospital (Tuebingen, Alemanya))
Le, Nhu D. (BC Cancer Agency (Vancover, Canadà))
Martin, Stewart G. (University of Nottingham (Nottingham, Regne Unit))
Menon, Usha (University College London (Londres, Anglaterra))
Modugno, Francesmary (Magee-Womens Research Institute and Hillman Cancer Center (Pittsburgh, Estats Units d'Amèrica))
Pharoah, Paul D. P. (University of Cambridge (Cambridge, Regne Unit))
Schildkraut, Joellen M. (Emory University (Atlanta, Estats Units d'Amèrica))
Sieh, Weiva (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
Staebler, Annette (Tuebingen University Hospital)
Sundfeldt, Karin (University of Gothenburg)
Swerdlow, Anthony J. (The Institute of Cancer Research (Londres, Anglaterra))
Ramus, Susan J. (University of NSW Sydney (New South Wales, Austràlia))
Brenton, James D. (University of Cambridge (Cambrige, Regne Unit))
Universitat Autònoma de Barcelona

Data:	2023
Resum:	Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93. 4% (4,630/4,957) in HGSC compared to 11. 9% (116/973) in EC and 11. 5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2. 18, 95% confidence interval [CI] 1. 36-3. 47, p = 0. 0011) and with CCC (HR = 1. 57, 95% CI 1. 11-2. 22, p = 0. 012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Ajuts:	Instituto de Salud Carlos III PI19/00640
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	TP53 ; Clear cell ; Endometrioid ; High-grade serous carcinoma ; Ovarian cancer ; P53 ; Prognosis
Publicat a:	Journal of Pathology: Clinical Research, Vol. 9 Núm. 3 (may 2023) , p. 208-222, ISSN 2056-4538

DOI: 10.1002/cjp2.311
PMID: 36948887

15 p, 1.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats